Sign In

Search |

Add/Edit My Facility

MSKCC-Antitumor Assessment Core Facility (Antitumor Assessment)

Subscribe to this Core


cite this facility

Primary Contact:

Elisa de Stanchina

Facility RRID

RRID:SCR_027795

Facility Details

The core supports early discovery and in vivo testing of antitumor detection and therapeutic agents. The ATA core works closely with investigators to establish preclinical models, including Patient-Derived Xenograft (PDX) and Organoid (PDO) models, and to design and execute pharmacokinetic (PK), tolerability, and in vivo efficacy studies in various mouse tumor models. Additionally, the Core performs GLP-compliant safety toxicology studies in support of IND applications for both diagnostic and therapeutic agents (small molecules, cell therapies, biologics) and can conduct PK studies in support of Phase I-II clinical trials.

Facility Policies

Services are offerred outside of

Consulting is offerred outside of Memorial Sloan Kettering Cancer Center

Last Updated: 04/14/2026